# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

# FORM 8-K

CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (date of earliest event reported): October 29, 2018

# **COMMUNITY HEALTH SYSTEMS, INC.**

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation) 001-15925 (Commission File Number) 13-3893191 (I.R.S. Employer Identification No.)

4000 Meridian Boulevard Franklin, Tennessee 37067 (Address of principal executive offices)

Registrant's telephone number, including area code: (615) 465-7000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Dere-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Dere-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  $\Box$ 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

The information contained in this Current Report on Form 8-K (including the exhibits hereto) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.

#### ITEM 2.02 Results of Operations and Financial Condition

On October 29, 2018, Community Health Systems, Inc. (the "Company") announced operating results for the third quarter ended September 30, 2018. A copy of the press release making this announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 2.02.

#### ITEM 7.01 Regulation FD Disclosure

The press release referred to in Item 2.02 above also includes the Company's 2018 updated annual earnings guidance. The 2018 guidance is based on the Company's historical operating performance, current trends and other assumptions the Company believes are reasonable at this time as set forth on pages 17, 18, 19 and 20 of the press release. A copy of the press release making this announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 7.01.

ITEM 9.01 Financial Statements and Exhibits

(d) Exhibits

The following exhibit is furnished herewith:

Exhibit NumberDescription99.1Community Health Systems, Inc. Press Release, dated October 29, 2018.

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

3

Date: October 29, 2018

# COMMUNITY HEALTH SYSTEMS, INC. (Registrant)

By: /s/ Wayne T. Smith

Wayne T. Smith Chairman of the Board and Chief Executive Officer (principal executive officer)

By: /s/ Thomas J. Aaron

Thomas J. Aaron Executive Vice President and Chief Financial Officer (principal financial officer)

By: /s/ Kevin J. Hammons

Kevin J. Hammons Senior Vice President, Assistant Chief Financial Officer, Chief Accounting Officer and Treasurer (principal accounting officer)



r Contact:	Thom
	Execu

Investo

Thomas J. Aaron Executive Vice President and Chief Financial Officer (615) 465-7000

#### COMMUNITY HEALTH SYSTEMS, INC. ANNOUNCES THIRD QUARTER 2018 RESULTS WITH NET OPERATING REVENUES OF \$3.451 BILLION

FRANKLIN, Tenn. (October 29, 2018) – Community Health Systems, Inc. (NYSE: CYH) (the "Company") today announced financial and operating results for the three and nine months ended September 30, 2018.

The following highlights the financial and operating results for the three months ended September 30, 2018.

- Net operating revenues totaled \$3.451 billion.
- Net loss attributable to Community Health Systems, Inc. common stockholders was \$(325) million, or \$(2.88) per share (diluted), compared with net loss of \$(110) million, or \$(0.98) per share (diluted), for the same period in 2017. Excluding the adjusting items as presented in the table in footnote (h) on page 15, net loss attributable to Community Health Systems, Inc. common stockholders was \$(1.64) per share (diluted), compared with \$(0.79) per share (diluted) for the same period in 2017.
- Adjusted EBITDA was \$372 million.
- Net cash provided by operating activities was \$346 million, compared with \$114 million for the same period in 2017.
- On a same-store basis, admissions decreased 2.3 percent and adjusted admissions decreased 0.8 percent, compared with the same period in 2017.

Net operating revenues for the three months ended September 30, 2018, totaled \$3.451 billion, a 5.9 percent decrease, compared with \$3.666 billion for the same period in 2017.

Net loss attributable to Community Health Systems, Inc. common stockholders was \$(325) million, or \$(2.88) per share (diluted), for the three months ended September 30, 2018, compared with \$(110) million, or \$(0.98) per share (diluted), for the same period in 2017. Excluding the adjusting items as presented in the table in footnote (h) on page 15, net loss attributable to Community Health Systems, Inc. common stockholders was \$(1.64) per share (diluted), for the three months ended September 30, 2018, compared with \$(0.79) per share (diluted) for the same period in 2017. Weighted-average shares outstanding (diluted) were 113 million for the three months ended September 30, 2018, and 112 million for the three months ended September 30, 2017.

Adjusted EBITDA for the three months ended September 30, 2018, was \$372 million compared with \$331 million for the same period in 2017, representing a 12.4 percent increase.

The consolidated operating results for the three months ended September 30, 2018, reflect a 12.4 percent decrease in total admissions, and a 12.2 percent decrease in total adjusted admissions, compared with the same period in 2017. On a same-store basis, admissions decreased 2.3 percent and adjusted admissions decreased 0.8 percent during the three months ended September 30, 2018, compared with the same period in 2017. On a same-store basis, net operating revenues increased 3.2 percent during the three months ended September 30, 2018, compared with the same period in 2017.

CYH Announces Third Quarter 2018 Results Page 2 October 29, 2018

Net operating revenues for the nine months ended September 30, 2018, totaled \$10.702 billion, a 13.0 percent decrease, compared with \$12.295 billion for the same period in 2017.

Net loss attributable to Community Health Systems, Inc. common stockholders was \$(460) million, or \$(4.08) per share (diluted), for the nine months ended September 30, 2018, compared with \$(446) million, or \$(3.99) per share (diluted), for the same period in 2017. Excluding the adjusting items as presented in the table in footnote (h) on page 15, net loss attributable to Community Health Systems, Inc. common stockholders was \$(1.52) per share (diluted) for the nine months ended September 30, 2018, compared with net loss of \$(0.98) per share (diluted) for the same period in 2017. Weighted-average shares outstanding (diluted) were 113 million for the nine months ended September 30, 2018, and 112 million for the nine months ended September 30, 2017.

Adjusted EBITDA for the nine months ended September 30, 2018, was \$1.223 billion compared with \$1.294 billion for the same period in 2017, representing a 5.5 percent decrease.

The consolidated operating results for the nine months ended September 30, 2018, reflect a 16.5 percent decrease in total admissions, and a 16.9 percent decrease in total adjusted admissions, compared with the same period in 2017. On a same-store basis, admissions decreased 2.4 percent and adjusted admissions decreased 0.9 percent during the nine months ended September 30, 2018, compared with the same period in 2017. On a same-store basis, net operating revenues increased 2.6 percent during the nine months ended September 30, 2018, compared with the same period in 2017.

On September 25, 2018, the Company issued a press release to announce a global resolution and settlement agreements ending the U.S. Department of Justice investigation into certain conduct of Health Management Associates, Inc. ("HMA") and its affiliated entities and settling qui tam lawsuits that were initiated and pending, and known to the Company, before the Company's acquisition by merger of HMA in 2014. The Company previously recorded an estimated liability at fair value of the remaining underlying claims that are covered by the CVR agreement as part of the acquisition accounting for HMA. This liability has been adjusted as of September 30, 2018, to take into account the settlement amount contemplated by the global settlement agreements, including interest, of \$266 million and has been reclassified as a current liability in other accrued liabilities on the condensed consolidated balance sheet at September 30, 2018. This settlement amount will be paid in the fourth quarter of 2018. In addition, certain components of the settlement payment are not considered deductible for income taxes because of recent changes to the U.S. tax code from the Tax Cuts and Jobs Act enacted in December 2017, which resulted in approximately \$23 million in deferred tax expense during the third quarter of 2018 from the write-off of the related deferred tax assets.

Commenting on the results, Wayne T. Smith, chairman and chief executive officer of Community Health Systems, Inc., said, "We are pleased with the progress we made in the third quarter, and we are encouraged by the momentum we are seeing from strategic and operational initiatives that have been implemented across our portfolio of hospitals. We are especially pleased with same store performance in many of our core markets. We believe our overall performance will continue to improve as we complete additional divestitures and direct our investments into markets where we have the greatest opportunities for growth."

During 2018, the Company has completed nine hospital divestitures. In addition, the Company has entered into definitive agreements to sell five additional hospitals, which divestitures have not yet been completed. The Company is pursuing additional interests for sale transactions involving hospitals, which, together with the hospitals that are currently subject to definitive agreements and the hospitals that have been divested during 2018, had a combined total of at least \$2.0 billion in annual net operating revenues and combined mid-single digit Adjusted EBITDA margins during 2017. These sale transactions are currently subject to definitive agreements). There can be no assurance that these potential divestitures (or the potential divestitures currently subject to definitive agreements) will be completed, or if they are completed, the ultimate timing of the completion of these divestitures. The Company continues to receive interest from potential acquirers for certain of its hospitals.

CYH Announces Third Quarter 2018 Results Page 3 October 29, 2018

Financial and statistical data for 2018 and 2017 presented in this press release includes the operating results of divested hospitals through the effective closing date of each respective divestiture. Same-store operating results exclude the results of the hospitals divested in 2018 and 2017.

#### **Information About Non-GAAP Financial Measures**

Adjusted EBITDA, a non-GAAP financial measure, is EBITDA adjusted to add back net income attributable to noncontrolling interests and to exclude the effect of discontinued operations, loss (gain) from early extinguishment of debt, impairment and (gain) loss on sale of businesses, gain on sale of investments in unconsolidated affiliates, expense incurred related to the spin-off of QHC, expense incurred related to the sale of a majority ownership interest in the Company's home care division, expense (income) related to government and other legal settlements and related costs, expense related to employee termination benefits and other restructuring charges, expense (income) from settlement and fair value adjustments on the CVR agreement liability related to the HMA legal proceedings and related legal expenses, and the overall impact of the change in estimate related to net patient revenue recorded in the fourth quarter of 2017 resulting from the increase in contractual allowances and the provision for bad debts.

For information regarding why the Company believes Adjusted EBITDA provides useful information to investors, and for a reconciliation of Adjusted EBITDA to net income attributable to Community Health Systems, Inc. stockholders, see footnote (e) to the Financial Highlights, Financial Statements and Selected Operating Data below.

Additionally, the Company has provided adjusted loss from continuing operations attributable to Community Health Systems, Inc. common stockholders per share (diluted) and adjusted net loss attributable to Community Health Systems, Inc. common stockholders per share (diluted) to reflect the impact on earnings per share from the selected items used in the calculation of Adjusted EBITDA. For a presentation and reconciliation of these measures, see footnote (h) to the Financial Highlights, Financial Statements and Selected Operating Data below.

Included on pages 17, 18, 19 and 20 of this press release are tables setting forth the Company's 2018 updated annual earnings guidance. The 2018 guidance is based on the Company's historical operating performance, current trends and other assumptions that the Company believes are reasonable at this time, and reflects the impact of planned divestitures in 2018.

Community Health Systems, Inc. is one of the largest publicly traded hospital companies in the United States and a leading operator of general acute care hospitals in communities across the country. The Company, through its subsidiaries, owns, leases or operates 117 affiliated hospitals in 20 states with an aggregate of approximately 19,000 licensed beds.

The Company's headquarters are located in Franklin, Tennessee, a suburb south of Nashville. Shares in Community Health Systems, Inc. are traded on the New York Stock Exchange under the symbol "CYH." More information about the Company can be found on its website at <u>www.chs.net</u>.

Community Health Systems, Inc. will hold a conference call on Tuesday, October 30, 2018, at 10:00 a.m. Central, 11:00 a.m. Eastern, to review financial and operating results for the third quarter ended September 30, 2018. Investors will have the opportunity to listen to a live Internet broadcast of the conference call by clicking on the Investor Relations link of the Company's website at <u>www.chs.net</u>. To listen to the live call, please go to the website at least fifteen minutes early to register, download and install any necessary audio software. For those who cannot listen to the live broadcast, a replay will be available shortly after the call and will continue to be available through November 30, 2018. Copies of this press release and conference call slide show, as well as the Company's Current Report on Form 8-K (including this press release), will be available on the Company's website at <u>www.chs.net</u>.

**Financial Highlights (a)(b)(c)(d)** (In millions, except per share amounts) (Unaudited)

	Three Months Ended September 30, 2018 2017		Nine Mon Septem 2018	
Net operating revenues (k)	\$ 3,451	\$ 3,666	\$10,702	\$12,295
Loss from continuing operations (f), (i), (j)	(308)	(88)	(405)	(380)
Net loss attributable to Community Health Systems, Inc. stockholders	(325)	(110)	(460)	(446)
Adjusted EBITDA (e)	372	331	1,223	1,294
Net cash provided by operating activities	346	114	440	617
Basic loss per share attributable to Community Health Systems, Inc. common stockholders:				
Continuing operations (f), (i), (j)	\$ (2.88)	\$ (0.96)	\$ (4.08)	\$ (3.91)
Discontinued operations		(0.02)		(0.08)
Net loss	\$ (2.88)	\$ (0.98)	\$ (4.08)	\$ (3.99)
Diluted loss per share attributable to Community Health Systems, Inc. common stockholders:				
Continuing operations (f), (h), (i), (j)	\$ (2.88)	\$ (0.96)	\$ (4.08)	\$ (3.91)
Discontinued operations		(0.02)		(0.08)
Net loss (h)	\$ (2.88)	\$ (0.98)	\$ (4.08)	\$ (3.99)
Weighted-average number of shares outstanding (g):				
Basic	113	112	113	112
Diluted	113	112	113	112

For footnotes, see pages 12, 13, 14, 15 and 16.

Condensed Consolidated Statements of Loss (a)(b)(c)(d) (In millions, except per share amounts)

(Unaudited)

	Three Months Ended September 30,					
		2018	2017			
	Amount	% of Net Operating Revenues	Amount	% of Net Operating Revenues		
Operating revenues (net of contractual allowances and discounts)			\$ 4,333			
Provision for bad debts			667			
Net operating revenues (k)	\$ 3,451	100.0 %	3,666	100.0 %		
Operating costs and expenses:						
Salaries and benefits	1,585	45.9 %	1,724	47.0 %		
Supplies	565	16.4 %	610	16.6 %		
Other operating expenses	858	24.9 %	911	24.9 %		
Government and other legal settlements and related costs (j)	2	0.1 %	1	— %		
Electronic health records incentive reimbursement	(1)	— %	(2)	— %		
Rent	83	2.4 %	93	2.5 %		
Depreciation and amortization	173	5.0 %	206	5.6 %		
Impairment and (gain) loss on sale of businesses, net (i)	112	3.2 %	33	0.9 %		
Total operating costs and expenses	3,377	97.9 %	3,576	97.5 %		
Income from operations (f), (i), (j)	74	2.1 %	90	2.5 %		
Interest expense, net	256	7.3 %	238	6.5 %		
Loss from early extinguishment of debt	27	0.8 %	4	0.1 %		
Equity in earnings of unconsolidated affiliates	(5)	(0.1)%	(5)	(0.1)%		
Loss from continuing operations before income taxes	(204)	(5.9)%	(147)	(4.0)%		
Provision for (benefit from) income taxes	104	3.0 %	(59)	(1.6)%		
Loss from continuing operations (f), (i), (j)	(308)	(8.9)%	(88)	(2.4)%		
Discontinued operations, net of taxes:						
Loss from operations of entities sold or held for sale		— %	(1)	— %		
Impairment of hospitals sold or held for sale	—	— %	(1)	— %		
Loss from discontinued operations, net of taxes		— %	(2)	(0.1)%		
Net loss	(308)	(8.9)%	(90)	(2.5)%		
Less: Net income attributable to noncontrolling interests	17	0.5 %	20	0.5 %		
Net loss attributable to Community Health Systems, Inc. stockholders	\$ (325)	(9.4)%	\$ (110)	(3.0)%		
Basic loss per share attributable to Community Health Systems, Inc. common stockholders:			<u>`</u>			
Continuing operations (f), (i), (j)	\$ (2.88)		\$ (0.96)			
Discontinued operations			(0.02)			
Net loss	\$ (2.88)		\$ (0.98)			
Diluted loss per share attributable to Community Health Systems, Inc. common stockholders:			<u>_</u> _			
Continuing operations (f), (h), (i), (j)	\$ (2.88)		\$ (0.96)			
Discontinued operations			(0.02)			
Net loss (h)	\$ (2.88)		\$ (0.98)			
Weighted-average number of shares outstanding (g):						
Basic	113		112			
Diluted	113		112			
Dilucu						

For footnotes, see pages 12, 13, 14, 15 and 16.

Condensed Consolidated Statements of Loss (a)(b)(c)(d) (In millions, except per share amounts)

(Unaudited)

		2	<u>Nine Months Enc</u> 018		, 017
	Ā	Amount	% of Net Operating Revenues	Amount	% of Net Operating Revenues
Operating revenues (net of contractual allowances and discounts)	_			\$ 14,323	
Provision for bad debts				2,028	
Net operating revenues (k)	\$	10,702	100.0 %	12,295	100.0 %
Operating costs and expenses:					
Salaries and benefits		4,850	45.3 %	5,704	46.4 %
Supplies		1,773	16.6 %	2,056	16.7 %
Other operating expenses		2,646	24.7 %	2,984	24.3 %
Government and other legal settlements and related costs (j)		9	0.1 %	(32)	(0.3)%
Electronic health records incentive reimbursement		(2)	— %	(25)	(0.2)%
Rent		257	2.4 %	306	2.5 %
Depreciation and amortization		531	5.0 %	665	5.4 %
Impairment and (gain) loss on sale of businesses, net (i)		314	2.9 %	363	3.0 %
Total operating costs and expenses		10,378	97.0 %	12,021	97.8 %
Income from operations (f), (i), (j)		324	3.0 %	274	2.2 %
Interest expense, net		720	6.7 %	706	5.7 %
(Gain) loss from early extinguishment of debt		(32)	(0.3)%	35	0.3 %
Equity in earnings of unconsolidated affiliates		(17)	(0.2)%	(13)	(0.1)%
Loss from continuing operations before income taxes		(347)	(3.2)%	(454)	(3.7)%
Provision for (benefit from) income taxes		58	0.6 %	(74)	(0.6)%
Loss from continuing operations (f), (i), (j)		(405)	(3.8)%	(380)	(3.1)%
Discontinued operations, net of taxes:					
Loss from operations of entities sold or held for sale			— %	(4)	— %
Impairment of hospitals sold or held for sale		—	— %	(6)	— %
Loss from discontinued operations, net of taxes		_	— %	(10)	(0.1)%
Net loss		(405)	(3.8)%	(390)	(3.2)%
Less: Net income attributable to noncontrolling interests		55	0.5 %	56	0.4 %
Net loss attributable to Community Health Systems, Inc. stockholders	\$	(460)	(4.3)%	\$ (446)	(3.6)%
<i>Basic loss per share attributable to Community Health Systems, Inc. common stockholders:</i>					
Continuing operations (f), (i), (j)	\$	(4.08)		\$ (3.91)	
Discontinued operations	Ψ	(1.00)		(0.08)	
Net loss	\$	(4.08)		\$ (3.99)	
	Ψ	(4.00)		φ (0.00)	
Diluted loss per share attributable to Community Health Systems, Inc. common stockholders:					
Continuing operations (f), (h), (i), (j)	\$	(4.08)		\$ (3.91)	
Discontinued operations				(0.08)	
Net loss (h)	\$	(4.08)		\$ (3.99)	
Weighted-average number of shares outstanding (g):					
Basic		113		112	
Diluted		113		112	

For footnotes, see pages 12, 13, 14, 15 and 16.

- -MORE-

Condensed Consolidated Statements of Comprehensive Loss

(In millions) (Unaudited)

	Three Mon Septem 2018		Nine Mon Septem 2018	
Net loss	\$ (308)	\$ (90)	\$ (405)	\$ (390)
Other comprehensive income (loss), net of income taxes:				
Net change in fair value of interest rate swaps, net of tax	2	5	26	8
Net change in fair value of available-for-sale securities, net of tax		2	(2)	7
Amortization and recognition of unrecognized pension cost components, net of tax		1	1	2
Other comprehensive income	2	8	25	17
Comprehensive loss	(306)	(82)	(380)	(373)
Less: Comprehensive income attributable to noncontrolling interests	17	20	55	56
Comprehensive loss attributable to Community Health Systems, Inc. stockholders	\$ (323)	\$ (102)	\$ (435)	\$ (429)

For footnotes, see pages 12, 13, 14, 15 and 16.

Selected Operating Data (a)(c) (Dollars in millions)

(Unaudited)

	Three Months Ended September 30,								
		2010	Coi	isolidated			2010	Same-Store	
Number of hospitals (at end of period)		2018		<u>2017</u> 133	<u>% Change</u>		<u>2018</u> 117	<u>2017</u> 117	<u>% Change</u>
		118							
Licensed beds (at end of period)		19,684		22,012			19,558	19,562	
Beds in service (at end of period)		17,294		19,616			17,184	17,369	
Admissions		50,730		171,994	-12.4%		148,786	152,261	-2.3%
Adjusted admissions	3	30,681	3	376,597	-12.2%	3	326,969	329,566	-0.8%
Patient days	6	69,035	5	756,186		6	561,106	671,487	
Average length of stay (days)		4.4		4.4			4.4	4.4	
Occupancy rate (average beds in service)		41.7%		41.8%			41.8%	42.0%	
Net operating revenues (k)	\$	3,451	\$	3,666	-5.9%	\$	3,434	\$ 3,329	3.2%
Net inpatient revenues as a % of net operating revenues		47.1%		47.6%			47.0%	47.8%	
Net outpatient revenues as a % of net operating revenues		52.9%		52.4%			53.0%	52.2%	
Income from operations (f), (i), (j)	\$	74	\$	90	-17.8%				
Income from operations as a % of net operating revenues		2.1%		2.5%					
Depreciation and amortization	\$	173	\$	206					
Equity in earnings of unconsolidated affiliates	\$	(5)	\$	(5)					
Net loss attributable to Community Health Systems, Inc.									
stockholders	\$	(325)	\$	(110)	-195.5%				
Net loss attributable to Community Health Systems, Inc.									
stockholders as a % of net operating revenues		-9.4%		-3.0%					
Adjusted EBITDA (e)	\$	372	\$	331	12.4%				
Adjusted EBITDA as a % of net operating revenues		10.8%		9.0%					
Net cash provided by operating activities	\$	346	\$	114	203.5%				

For footnotes, see pages 12, 13, 14, 15 and 16.

Selected Operating Data (a)(c) (Dollars in millions)

(Unaudited)

	Nine Months Ended September 30,									
			Con	solidated			•	Sar	ne-Store	
		2018		2017	% Change		2018		2017	% Change
Number of hospitals (at end of period)		118		133			117		117	
Licensed beds (at end of period)		19,684		22,012			19,558		19,562	
Beds in service (at end of period)		17,294		19,616			17,184		17,369	
Admissions		478,919		573,671	-16.5%		459,100		470,345	-2.4%
Adjusted admissions	1	,031,390	1	,241,327	-16.9%		990,839	1	,000,241	-0.9%
Patient days	2	,150,553	2	,569,587		2	2,069,294	2	,105,434	
Average length of stay (days)		4.5		4.5			4.5		4.5	
Occupancy rate (average beds in service)		43.6%		43.5%			44.0%		44.4%	
Net operating revenues (k)	\$	10,702	\$	12,295	-13.0%	\$	10,396	\$	10,131	2.6%
Net inpatient revenues as a % of net operating										
revenues		47.8%		47.9%			47.6%		48.5%	
Net outpatient revenues as a % of net operating										
revenues		52.2%		52.1%			52.4%		51.5%	
Income from operations (f), (i), (j)	\$	324	\$	274	18.2%					
Income from operations as a % of net operating										
revenues		3.0%		2.2%						
Depreciation and amortization	\$	531	\$	665						
Equity in earnings of unconsolidated affiliates	\$	(17)	\$	(13)						
Net loss attributable to Community Health										
Systems, Inc. stockholders	\$	(460)	\$	(446)	-3.1%					
Net loss attributable to Community Health										
Systems, Inc. stockholders as a % of net										
operating revenues		-4.3%		-3.6%						
Adjusted EBITDA (e)	\$	1,223	\$	1,294	-5.5%					
Adjusted EBITDA as a % of net operating										
revenues		11.4%		10.5%						
Net cash provided by operating activities	\$	440	\$	617	-28.7%					

For footnotes, see pages 12, 13, 14, 15 and 16.

Condensed Consolidated Balance Sheets

(In millions, except share data)

(Unaudited)

	<u>September 30, 2018</u>		Decen	iber 31, 2017
ASSETS				
Current assets				
Cash and cash equivalents	\$	335	\$	563
Patient accounts receivable (k)		2,347		2,384
Supplies		424		444
Prepaid income taxes		17		17
Prepaid expenses and taxes		191		198
Other current assets		410		462
Total current assets		3,724		4,068
Property and equipment, gross		10,986		11,497
Less accumulated depreciation and amortization		(4,416)		(4,445)
Property and equipment, net		6,570		7,052
Goodwill		4,631		4,723
Deferred income taxes		_		62
Other assets, net		1,544		1,545
Total assets	\$	16,469	\$	17,450
LIABILITIES AND STOCKHOLDERS' DEFICIT				
Current liabilities				
Current maturities of long-term debt	\$	35	\$	33
Accounts payable		816		967
Accrued liabilities:				
Employee compensation		630		685
Accrued interest		258		229
Other (b)		740		442
Total current liabilities		2,479		2,356
Long-term debt (l)		13,535		13,880
Deferred income taxes		39		19
Other long-term liabilities (b)		1,051		1,360
Total liabilities		17,104		17,615
Redeemable noncontrolling interests in equity of consolidated subsidiaries		495		527
STOCKHOLDERS' DEFICIT				
Community Health Systems, Inc. stockholders' deficit:				
Preferred stock, \$.01 par value per share, 100,000,000 shares authorized; none issued				
Common stock, \$.01 par value per share, 300,000,000 shares authorized; 116,245,071				
shares issued and outstanding at September 30, 2018, and 114,651,004 shares issued and				
outstanding at December 31, 2017		1		1
Additional paid-in capital		2,011		2,014
Accumulated other comprehensive loss		(8)		(21)
Accumulated deficit		(3,209)		(2,761)
Total Community Health Systems, Inc. stockholders' deficit		(1,205)		(767)
Noncontrolling interests in equity of consolidated subsidiaries		75		75
Total stockholders' deficit		(1,130)		(692)
Total liabilities and stockholders' deficit	\$	16,469	\$	17,450

For footnotes, see pages 12, 13, 14, 15 and 16.

**Condensed Consolidated Statements of Cash Flows** (In millions)

(Unaudited)

			ded September 30,		
Cash flows from operating activities		2018		2017	
Net loss	\$	(405)	\$	(390)	
Adjustments to reconcile net loss to net cash provided by operating activities:	ψ	(403)	Ψ	(550)	
Depreciation and amortization		531		665	
Government and other legal settlements and related costs (j)		9		8	
Stock-based compensation expense		10		20	
Impairment of hospitals sold or held for sale		10		6	
Impairment of hospitals sold of held for sale Impairment and (gain) loss on sale of businesses, net (i)		314		363	
(Gain) loss from early extinguishment of debt		(32)		35	
Other non-cash expenses, net		25		24	
Changes in operating assets and liabilities, net of effects of acquisitions and divestitures:		23		24	
Patient accounts receivable		38		229	
		30 14			
Supplies, prepaid expenses and other current assets				(37)	
Accounts payable, accrued liabilities and income taxes		(47)		(215)	
Other	. <u></u>	(17)		(91)	
Net cash provided by operating activities		440		617	
Cash flows from investing activities					
Acquisitions of facilities and other related businesses		(21)		(4)	
Purchases of property and equipment		(413)		(428)	
Proceeds from disposition of hospitals and other ancillary operations		228		1,666	
Proceeds from sale of property and equipment		7		4	
Purchases of available-for-sale securities and equity securities		(50)		(85)	
Proceeds from sales of available-for-sale securities and equity securities		75		133	
Increase in other investments		(76)		(95)	
Net cash (used in) provided by investing activities		(250)		1,191	
Cash flows from financing activities					
Repurchase of restricted stock shares for payroll tax withholding requirements		(1)		(5)	
Deferred financing costs and other debt-related costs		(93)		(66)	
Proceeds from noncontrolling investors in joint ventures		2		5	
Redemption of noncontrolling investments in joint ventures		(27)		(5)	
Distributions to noncontrolling investors in joint ventures		(74)		(79)	
Borrowings under credit agreements		24		839	
Issuance of long-term debt		1,033		3,100	
Proceeds from ABL and receivables facility		587		26	
Repayments of long-term indebtedness		(1,869)		(5,271)	
Net cash used in financing activities	. <u></u>	(418)		(1,456)	
Net change in cash and cash equivalents		(228)		352	
Cash and cash equivalents at beginning of period		563		238	
	<u>م</u>		¢		
Cash and cash equivalents at end of period	\$	335	\$	590	

For footnotes, see pages 12, 13, 14, 15 and 16.

- (a) Continuing operating results exclude discontinued operations for the three and nine months ended September 30, 2018 and 2017. Both financial and statistical results exclude entities in discontinued operations for all periods presented. In addition, financial and statistical results include the operating results of divested hospitals through the effective closing date of each respective divestiture. Same-store operating results exclude the results of the hospitals divested in 2018 and 2017.
- (b) The contingent value right ("CVR") was issued to shareholders of Health Management Associates, Inc. ("HMA") as part of the merger consideration in the Company's acquisition by merger of HMA in 2014 (the "HMA Merger"). The CVR entitles the holder to receive a cash payment up to \$1.00 per CVR (subject to downward adjustment but not below zero), subject to the final resolution of certain legal matters pertaining to HMA, as defined in the CVR agreement. If the aggregate amount of applicable losses under the CVR agreement exceeds a deductible of \$18 million, then the amount payable in respect of each CVR shall be reduced (but not below zero) by an amount equal to the quotient obtained by dividing: (a) the product of (i) all losses in excess of the deductible and (ii) 90%; by (b) the number of CVRs outstanding on the date on which final resolution of the existing litigation occurs.

On September 25, 2018, the Company issued a press release to announce a global resolution and settlement agreements ending the U.S. Department of Justice investigation into certain conduct of HMA and its affiliated entities and settling qui tam lawsuits that were initiated and pending, and known to the Company, before the HMA Merger. Since the HMA acquisition date of January 27, 2014, prior to giving effect to the global settlement as noted in the table below, approximately \$36 million in costs have been incurred and approximately \$30 million of settlements have been paid related to certain HMA legal matters, which collectively exceed the deductible of \$18 million under the CVR agreement. The Company previously recorded an estimated liability at fair value of the remaining underlying claims that are covered by the CVR agreement as part of the acquisition accounting for HMA. This liability has been adjusted as of September 30, 2018, to take into account the settlement amount contemplated by the global settlement agreements, including interest, of \$266 million and has been reclassified as a current liability in other accrued liabilities on the condensed consolidated balance sheet at September 30, 2018. This settlement amount will be paid in the fourth quarter of 2018. In addition, although future legal fees (which are expensed as incurred) and any attorney fees claimed for reimbursement by the relators associated with the HMA legal matters (including the global settlement noted above) have not been accrued or included in the table below, such legal fees and attorney fees are to be taken into account in determining the total amount of reductions applied to the amounts owed to CVR holders. The Company is currently in the process of reviewing the final payment amount required for the CVR as defined in the CVR agreement. However, based on the total costs incurred and settlements paid (including with respect to the global settlement) as summarized below, the Company anticipates that no payment will be due to the CVR h

The following table presents the impact of the paid and recorded amounts as described above as applied to the CVR and the \$18 million deductible and 10% co-insurance amounts (in millions):

	Septe	As of mber 30, 2018
Legal and other related costs incurred to date	\$	36
Settlements paid		30
Settlements accrued based on final amounts		266
Estimated liability for unresolved contingencies		
Costs incurred plus certain estimated liabilities for CVR-related matters		332
Allocated to:		
CHS deductible of \$18 million		(18)
CHS co-insurance at 10%		(29)
Recorded amounts that reduce CVR value after giving effect to deductible and		
co-insurance	\$	285
CVRs outstanding		265

(c) Included in discontinued operations for the three and nine months ended September 30, 2017, are three smaller hospitals, one of which is being actively marketed for sale (and is no longer separately presented as discontinued operations) and two hospitals that have been sold. The after-tax loss for the sold or held for sale hospitals, was approximately \$2 million and \$10 million for the three and nine months ended September 30, 2017, respectively.

(d) The following table provides information needed to calculate loss per share, which is adjusted for income attributable to noncontrolling interests (in millions):

	Three Mor Septem		Nine Mon Septem	
	2018	2017	2018	2017
Loss from continuing operations attributable to Community Health Systems, Inc. common stockholders:				
Loss from continuing operations, net of taxes	\$ (308)	\$ (88)	\$ (405)	\$ (380)
Less: Income from continuing operations attributable to noncontrolling interests, net of taxes	17	20	55	56
Loss from continuing operations attributable to Community Health Systems, Inc. common stockholders — basic and diluted	\$ (325)	\$ (108)	\$ (460)	\$ (436)
Loss from discontinued operations attributable to Community Health Systems, Inc. common stockholders:				
Loss from discontinued operations, net of taxes	\$ —	\$ (2)	\$ —	\$ (10)
Less: Loss from discontinued operations attributable to noncontrolling interests, net of taxes		_	_	_
Loss from discontinued operations attributable to Community Health Systems, Inc. common stockholders — basic and diluted	\$	<u>\$ (2)</u>	\$	<u>\$ (10)</u>

EBITDA is a non-GAAP financial measure which consists of net loss attributable to Community Health Systems, Inc. before interest, income (e) taxes, and depreciation and amortization. Adjusted EBITDA, also a non-GAAP financial measure, is EBITDA adjusted to add back net income attributable to noncontrolling interests and to exclude the effect of discontinued operations, loss (gain) from early extinguishment of debt, impairment and (gain) loss on sale of businesses, gain on sale of investments in unconsolidated affiliates, expense incurred related to the spin-off of QHC, expense incurred related to the sale of a majority ownership interest in the Company's home care division, expense (income) related to government and other legal settlements and related costs, expense related to employee termination benefits and other restructuring charges, expense (income) from settlement and fair value adjustments on the CVR agreement liability related to the HMA legal proceedings and related legal expenses, and the overall impact of the change in estimate related to net patient revenue recorded in the fourth quarter of 2017 resulting from the increase in contractual allowances and the provision for bad debts. The Company has from time to time sold noncontrolling interests in certain of its subsidiaries or acquired subsidiaries with existing noncontrolling interest ownership positions. The Company believes that it is useful to present Adjusted EBITDA because it adds back the portion of EBITDA attributable to these third-party interests and clarifies for investors the Company's portion of EBITDA generated by continuing operations. The Company reports Adjusted EBITDA as a measure of financial performance. Adjusted EBITDA is a key measure used by management to assess the operating performance of the Company's hospital operations and to make decisions on the allocation of resources. Adjusted EBITDA is also used to evaluate the performance of the Company's executive management team and is one of the primary targets used to determine short-term cash incentive compensation. In addition, management utilizes Adjusted EBITDA in assessing the Company's consolidated results of operations and operational performance and in comparing the Company's results of operations between periods. The Company believes it is useful to provide investors and other users of the Company's financial statements this performance measure to align with how management assesses the Company's results of operations. Adjusted EBITDA also is comparable to a similar metric called Consolidated EBITDA, as defined in the Company's senior secured credit facility, which is a key component in the determination of the Company's compliance with some of the covenants under the Company's senior secured credit facility (including the Company's ability to service debt and incur capital expenditures), and is used to determine the interest rate and commitment fee payable under the senior secured credit facility (although Adjusted EBITDA does not include all of the adjustments described in the senior secured credit facility).

Adjusted EBITDA is not a measurement of financial performance under U.S. GAAP. It should not be considered in isolation or as a substitute for net income, operating income, or any other performance measure calculated in accordance with U.S. GAAP. The items excluded from Adjusted EBITDA are significant components in understanding and evaluating financial performance. The Company believes such adjustments are appropriate as the magnitude and frequency of such items can vary significantly and are not related to the assessment of normal operating performance. Additionally, this calculation of Adjusted EBITDA may not be comparable to similarly titled measures reported by other companies.

The following table reflects the reconciliation of Adjusted EBITDA, as defined, to net loss attributable to Community Health Systems, Inc. stockholders as derived directly from the condensed consolidated financial statements (in millions):

	Three Mon Septem 2018		Nine Mon Septem 2018	
Net loss attributable to Community Health Systems, Inc. stockholders	\$ (325)	\$ (110)	\$ (460)	\$ (446)
Adjustments:				
Provision for (benefit from) income taxes	104	(59)	58	(74)
Depreciation and amortization	173	206	531	665
Net income attributable to noncontrolling interests	17	20	55	56
Loss from discontinued operations	_	2		10
Interest expense, net	256	238	720	706
Loss (gain) from early extinguishment of debt	27	4	(32)	35
Impairment and (gain) loss on sale of businesses, net	112	33	314	363
Expense (income) from government and other legal settlements and related costs	2	1	9	(32)
Expense (income) from settlement and fair value adjustments and legal expenses				
related to cases covered by the CVR	4	(6)	13	6
Expense related to the sale of a majority interest in home care division		—	—	1
Expense related to employee termination benefits and other restructuring charges	2	2	15	4
Adjusted EBITDA	\$ 372	\$ 331	\$1,223	\$1,294

(f) Included in non-same-store loss from operations and loss from continuing operations are pre-tax charges related to acquisition costs of less than \$1 million for both the three-month periods ended September 30, 2018 and 2017, and \$2 million and \$1 million for the nine-month periods ended September 30, 2018 and 2017, respectively.

(g) The following table sets forth components reconciling the basic weighted-average number of shares to the diluted weighted-average number of shares (in millions):

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2018	2017	2018	2017
Weighted-average number of shares outstanding - basic	113	112	113	112
Add effect of dilutive securities:				
Stock awards and options	—	—	—	
Weighted-average number of shares outstanding - diluted	113	112	113	112

The Company generated a loss from continuing operations attributable to Community Health Systems, Inc. common stockholders for the three and nine months ended September 30, 2018 and 2017, so the effect of dilutive securities is not considered because their effect would be antidilutive. If the Company had generated income from continuing operations, the effect of restricted stock awards on the diluted shares calculation would have been an increase of 4,001 shares and 148,768 shares during the three months ended September 30, 2018 and 2017, respectively, and 41,705 shares and 147,618 shares during the nine months ended September 30, 2018 and 2017, respectively.

(h) The following supplemental tables reconcile loss from continuing operations and net loss attributable to Community Health Systems, Inc. common stockholders, as reported, on a per share (diluted) basis, with the adjustments described herein (total per share amounts may not add due to rounding). The Company believes that the presentation of non-GAAP adjusted loss from continuing operations per share (diluted) and non-GAAP adjusted net loss attributable to Community Health Systems, Inc. common stockholders presents useful information to investors through highlighting the impact on earnings per share of selected items used in calculating Adjusted EBITDA.

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2018	2017	2018	2017
Loss from continuing operations, as reported	\$ (2.88)	\$ (0.96)	\$ (4.08)	\$ (3.91)
Adjustments:				
Loss (gain) from early extinguishment of debt	0.19	0.02	(0.22)	0.20
Impairment and (gain) loss on sale of businesses, net	0.79	0.19	2.32	2.87
Expense (income) from government and other legal settlements and related costs	0.01	0.01	0.06	(0.19)
Expense (income) from settlement and fair value adjustments and legal expenses				
related to cases covered by the CVR	0.03	(0.04)	0.09	0.05
Expense related to employee termination benefits and other restructuring charges	0.02	0.01	0.11	0.03
Tax effect of non-deductible portion of HMA legal settlement	0.21		0.21	—
Loss from continuing operations, excluding adjustments	\$ (1.64)	\$ (0.77)	\$(1.52)	\$ (0.95)

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2018	2017	2018	2017
Net loss, as reported	\$ (2.88)	\$ (0.98)	\$ (4.08)	\$ (3.99)
Adjustments:				
Loss (gain) from early extinguishment of debt	0.19	0.02	(0.22)	0.20
Impairment and (gain) loss on sale of businesses, net	0.79	0.19	2.32	2.87
Expense (income) from government and other legal settlements and related costs	0.01	0.01	0.06	(0.19)
Expense (income) from settlement and fair value adjustments and legal expenses				
related to cases covered by the CVR	0.03	(0.04)	0.09	0.05
Expense related to employee termination benefits and other restructuring charges	0.02	0.01	0.11	0.03
Tax effect of non-deductible portion of HMA legal settlement	0.21	_	0.21	
Impairment of long-lived assets in discontinued operations	—	0.01		0.05
Net loss, excluding adjustments	\$ (1.64)	\$ (0.79)	\$(1.52)	\$ (0.98)

- (i) Both income from operations and loss from continuing operations for the three and nine months ended September 30, 2018, included non-cash expense of approximately \$112 million and \$314 million, respectively, related to impairment charges to reduce the value of long-lived assets, including allocated goodwill, at hospitals that the Company has identified for sale or sold. Both income from operations and loss from continuing operations for the three and nine months ended September 30, 2017, included non-cash expense of approximately \$33 million and \$363 million, respectively, related to impairment charges to reduce the value of long-lived assets, including allocated goodwill, at hospitals that the Company has identified for sale or sold. These impairment charges do not have an impact on the calculation of the Company's financial covenants under the Company's Credit Facility.
- (j) The \$(0.01) per share (diluted) and \$(0.06) per share (diluted) of expense for "Government and other legal settlements and related costs" for the three and nine months ended September 30, 2018, respectively, is the net impact of several lawsuits settled in principle during the related periods, and related legal expenses. The \$(0.01) per share (diluted) of expense for "Government and other legal settlements and related costs" for the three months ended September 30, 2017, is the settlement in principle of several lawsuits during the three months ended September 30, 2017, and related legal expenses. The \$0.19 per share (diluted) of income for "Government and other legal settlements and related costs" for the nine months ended September 30, 2017, is primarily the impact of the shareholder derivative action settled during the nine months ended September 30, 2017, net of related legal expenses.
- (k) On January 1, 2018, the Company adopted the new revenue recognition accounting standard issued by the Financial Accounting Standards Board ("FASB") and codified in the FASB Accounting Standards Codification ("ASC") as topic 606 ("ASC 606"). The revenue recognition standard in ASC 606 outlines a single comprehensive model for recognizing revenue as performance obligations, defined in a contract with a customer as goods or services transferred to the customer in exchange for consideration, are satisfied.

The Company applied the modified retrospective approach to all contracts when adopting ASC 606. As a result, the majority of what was previously classified as the provision for bad debts in the statement of loss is now reflected as implicit price concessions (as defined in ASC 606) and therefore included as a reduction to net operating revenues in 2018. For changes in credit issues not assessed at the date of service, the Company will prospectively recognize those amounts as a component of operating costs and expenses. For periods prior to the adoption of ASC 606, the provision for bad debts has been presented consistent with the previous revenue recognition standards that required it to be presented separately as a component of net operating revenues. Additionally, upon adoption of ASC 606 the allowance for doubtful accounts of approximately \$3.9 billion at December 31, 2017 was reclassified as a component of net patient accounts receivable.

(I) For the 12-month period ended September 30, 2018, the first lien net debt to consolidated EBITDA leverage ratio financial covenant under the Company's Credit Facility limited the ratio of first lien net debt to consolidated EBITDA, as defined, to less than or equal to 5.0 to 1.00. We were in compliance with all such covenants at September 30, 2018, with a first lien net debt to consolidated EBITDA leverage ratio of approximately 4.6 to 1.00.

#### **Regulation FD Disclosure**

Set forth below is selected information concerning the Company's projected consolidated operating results for the year ending December 31, 2018. These projections update selected guidance provided on July 26, 2018, and are based on the Company's historical operating performance, current trends and other assumptions that the Company believes are reasonable at this time. The 2018 guidance should be considered in conjunction with the assumptions included herein. See pages 19 and 20 for a list of factors that could affect the future results of the Company or the healthcare industry generally.

The following is provided as guidance to analysts and investors:

	2018 Projection Range			
Net operating revenues (in millions)	\$ 14,000	to	\$	14,200
Adjusted EBITDA (in millions)	\$ 1,600	to	\$	1,650
Loss from continuing operations per share - diluted	\$ (2.25)	to	\$	(2.10)
Same-store hospital annual adjusted admissions	(1.0)%	to		— %
Weighted-average diluted shares	11	3 million	ı	

The following assumptions were used in developing the 2018 guidance provided above:

- The 2018 projections include the impact of completed divestitures and announced divestitures subject to a definitive agreement expected to close in 2018.
- The Company's projections also exclude the following:
  - Effect of debt refinancing activities, including gains and losses from early extinguishment of debt;
  - Impairment of goodwill and long-lived assets;
  - Gains or losses from the sales of businesses;
  - Employee termination benefits and restructuring costs;
  - Resolution of government investigations or other significant legal settlements, including the \$266 million HMA legal global settlement that will be paid in the fourth quarter of 2018;
  - Costs incurred in connection with divestitures;
  - Insurance recoveries that may be received for property losses and business interruption coverage related to Hurricanes Harvey, Irma, Florence and Michael;
  - Changes in the estimated impact of the Tax Cuts and Jobs Act ("Tax Act") on our deferred tax assets and liabilities; and
  - Other significant gains or losses that neither relate to the ordinary course of business nor reflect the Company's underlying business performance.

Other assumptions used in the above guidance:

- Health Information Technology (HITECH) electronic health records incentive reimbursement will be zero for the year ending December 31, 2018.
- Same-store hospital annual adjusted admissions decline of (1.0)% to 0.0% for 2018, which does not take into account service closures and weather-related or other unusual events.

CYH Announces Third Quarter 2018 Results Page 18 October 29, 2018

- Expressed as a percentage of net operating revenues, depreciation and amortization of approximately 5.0% for 2018. Additionally, this is a fixed cost and the percentages may change as revenue varies. Such amounts exclude the possible impact of any future hospital fixed asset impairments.
- Interest expense, expressed as a percentage of net operating revenues, of approximately 7.0%; however, interest expense may vary as revenue varies. Interest expense has been adjusted to reflect the repayment of debt with proceeds from the divestitures noted above, based on the expected timing of those divestitures. Total fixed rate debt, including swaps, is expected to average approximately 90% to 95% of total debt during 2018.
- Expressed as a percentage of net operating revenues, net income attributable to noncontrolling interests of approximately 0.5% for 2018.
- Expressed as a percentage of net operating revenues, provision for income taxes of approximately 0.7% to 0.8% for 2018.

A reconciliation of the Company's projected 2018 Adjusted EBITDA, a forward-looking non-GAAP financial measure, to the Company's projected net loss attributable to Community Health Systems, Inc. stockholders, the most directly comparable GAAP financial measure, is shown below:

	Year Ending December 31, 2018	
	Low	High
Net loss attributable to Community Health Systems, Inc. stockholders (1)	\$ (254)	\$ (237)
Adjustments:		
Depreciation and amortization	700	710
Interest expense, net	980	990
Provision for income taxes	104	112
Net income attributable to noncontrolling interests	70	75
Adjusted EBITDA (1)	\$1,600	\$1,650

- (1) The Company does not include in this reconciliation the impact of certain items not included in the Company's forecast set forth above that would be included in a reconciliation of historical net loss attributable to Community Health Systems, Inc. stockholders to Adjusted EBITDA such as, but not limited to, (gains) losses from early extinguishment of debt, impairment and (gain) loss on sale of businesses, and expense (income) related to government and other legal settlements and related costs, in light of the fact that such items are not determinable, and/or the inherent difficulty in quantifying such projected amounts, on a forward-looking basis.
- Capital expenditures are projected as follows (in millions):

	2018 Guidance		
Total	\$500	to	\$575

 Net cash provided by operating activities, excluding the payment of the HMA legal global settlement noted above, and including accelerated interest payments of approximately \$60 million and increased interest payments from higher interest rates of approximately \$65 million associated with debt refinancing, is projected as follows (in millions):

		2018 Guidance		
Total	\$550	to	\$650	

• Diluted weighted-average shares outstanding are projected to be approximately 113.0 million for 2018.

CYH Announces Third Quarter 2018 Results Page 19 October 29, 2018

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995 that involve risk and uncertainties. All statements in this press release other than statements of historical fact, including statements regarding projections, expected operating results, and other events that depend upon or refer to future events or conditions or that include words such as "expects," "anticipates," "intends," "plans," "believes," "estimates," "thinks," and similar expressions, are forward-looking statements. Although the Company believes that these forward-looking statements are based on reasonable assumptions, these assumptions are inherently subject to significant economic and competitive uncertainties and contingencies, which are difficult or impossible to predict accurately and may be beyond the control of the Company. Accordingly, the Company cannot give any assurance that its expectations will in fact occur and cautions that actual results may differ materially from those in the forward-looking statements. A number of factors could affect the future results of the Company or the healthcare industry generally and could cause the Company's expected results to differ materially from those expressed in this press release.

These factors include, among other things:

- general economic and business conditions, both nationally and in the regions in which we operate;
- the impact of changes made to the Affordable Care Act, the potential for repeal or additional changes to the Affordable Care Act, its implementation or its interpretation (including through executive orders), as well as changes in other federal, state or local laws or regulations affecting our business;
- the extent to which states support increases, decreases or changes in Medicaid programs, implement health insurance exchanges or alter the provision of healthcare to state residents through regulation or otherwise;
- the future and long-term viability of health insurance exchanges and potential changes to the beneficiary enrollment process;
- risks associated with our substantial indebtedness, leverage and debt service obligations, and the fact that a substantial portion of our indebtedness will mature and become due in the near future, including our ability to refinance such indebtedness on acceptable terms or to incur additional indebtedness;
- demographic changes;
- changes in, or the failure to comply with, governmental regulations;
- potential adverse impact of known and unknown government investigations, audits, and federal and state false claims act litigation and other legal proceedings;
- our ability, where appropriate, to enter into and maintain provider arrangements with payors and the terms of these arrangements, which may be further affected by the increasing consolidation of health insurers and managed care companies and vertical integration efforts involving payors and healthcare providers;
- changes in, or the failure to comply with, contract terms with payors and changes in reimbursement rates paid by federal or state healthcare programs or commercial payors;
- any potential additional impairments in the carrying value of goodwill, other intangible assets, or other long-lived assets, or changes in the useful lives of other intangible assets;
- changes in inpatient or outpatient Medicare and Medicaid payment levels and methodologies;
- the effects related to the continued implementation of the sequestration spending reductions and the potential for future deficit reduction legislation;
- increases in the amount and risk of collectability of patient accounts receivable, including decreases in collectability which may result from, among other things, self-pay growth and difficulties in recovering payments for which patients are responsible, including co-pays and deductibles;

- the efforts of insurers, healthcare providers, large employer groups and others to contain healthcare costs, including the trend toward value-based purchasing;
- our ongoing ability to demonstrate meaningful use of certified electronic health record technology and recognize income for the related Medicare or Medicaid incentive payments, to the extent such payments have not expired;
- increases in wages as a result of inflation or competition for highly technical positions and rising supply and drug costs due to market pressure from pharmaceutical companies and new product releases;
- liabilities and other claims asserted against us, including self-insured malpractice claims;
- competition;
- our ability to attract and retain, at reasonable employment costs, qualified personnel, key management, physicians, nurses and other healthcare workers;
- trends toward treatment of patients in less acute or specialty healthcare settings, including ambulatory surgery centers or specialty hospitals;
- changes in medical or other technology;
- changes in U.S. generally accepted accounting principles;
- the availability and terms of capital to fund any additional acquisitions or replacement facilities or other capital expenditures;
- our ability to successfully make acquisitions or complete divestitures, including the disposition of hospitals and non-hospital businesses pursuant to our portfolio rationalization and deleveraging strategy, our ability to complete any such acquisitions or divestitures on desired terms or at all (including to realize the anticipated amount of proceeds from contemplated dispositions), the timing of the completion of any such acquisitions or divestitures, and our ability to realize the intended benefits from any such acquisitions or divestitures;
- the impact that changes in our relationships with joint venture or syndication partners could have on effectively operating our hospitals or ancillary services or in advancing strategic opportunities;
- our ability to successfully integrate any acquired hospitals, or to recognize expected synergies from acquisitions;
- the impact of seasonal severe weather conditions, including the timing and amount of insurance recoveries in relation to severe weather events;
- our ability to obtain adequate levels of general and professional liability insurance;
- timeliness of reimbursement payments received under government programs;
- effects related to outbreaks of infectious diseases;
- the impact of prior or potential future cyber-attacks or security breaches;
- any failure to comply with the terms of the Corporate Integrity Agreement;
- the concentration of our revenue in a small number of states;
- our ability to realize anticipated cost savings and other benefits from our current strategic and operational cost savings initiatives;
- changes in interpretations, assumptions and expectations regarding the Tax Act; and
- the other risk factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2017, filed with the Securities and Exchange Commission on February 28, 2018, and our other public filings with the Securities and Exchange Commission.

The consolidated operating results for the three and nine months ended September 30, 2018, are not necessarily indicative of the results that may be experienced for any future periods. The Company cautions that the projections for calendar year 2018 set forth in this press release are given as of the date hereof based on currently available information. The Company undertakes no obligation to revise or update any forward-looking statements, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

-END-